China
Africa
Explore chapters and articles related to this topic
Pediatric Oncology
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Stephen Lowis, Rachel Cox, John Moppett, Helen Rees
There is evidence too that young adult patients with “pediatric”-type tumors benefit from a pediatric approach. The borders between adult and pediatric patients are increasingly blurred, and a new specialty of adolescent or young adult oncology has grown.
Paediatric oncology
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2014
Stephen Lowis, Rachel Cox, John Moppett, Antony Ng
The rarity of paediatric tumours is such that meaningful information regarding management can rarely be obtained in a single centre. For this reason, multi-centre collaborative approaches have been in place almost from the inception of paediatric oncology as a specialty, and it has long been accepted that all patients should be treated according to investigational studies wherever possible. This has been advantageous to the population as a whole, with a progressive improvement in survival of patients with many types of malignancies, and to individuals for whom a monitored and coherent treatment strategy offers the best chance of cure. There is also evidence that young adult patients with paediatric type tumours benefit from a paediatric approach. The borders between adult and paediatric patients are increasingly blurred, and a new specialty of adolescent or young adult oncology has grown.
The effects of individual- and network-level factors on discussion of cancer experiences: Survivors of childhood cancer in Korea
Published in Journal of Psychosocial Oncology, 2018
Min Ah Kim, Jaehee Yi, Kort C. Prince, Elizabeth Nagelhout, Yelena P. Wu
We recruited 78 young adult survivors diagnosed with cancer prior to age 19 and aged 19 to 39 years at the time of the study. There is no set age range of young adult cancer survivors in South Korea; therefore, this study adopted the U.S. standards of adolescent and young adult (AYA) cancer survivors who are aged 15 to 39 in accordance with the National Cancer Institute Adolescent and Young Adult Oncology Progress Review Group (2006). In this study, adolescents under 18 years of age were excluded based on South Korea's educational system: most adolescents usually graduate from their high school by age 18. Two respondents did not meet the study inclusion criterion, and eight failed to complete their survey information. The final sample for this study included 68 survivors of childhood cancer in Korea.
A review of current induction strategies and emerging prognostic factors in the management of children and adolescents with acute lymphoblastic leukemia
Published in Expert Review of Hematology, 2020
Saveria Capria, Matteo Molica, Sara Mohamed, Simona Bianchi, Maria Luisa Moleti, Silvia Maria Trisolini, Sabina Chiaretti, Anna Maria Testi
In 2006, the National Cancer Institute Adolescent and Young Adult Oncology Progress Review Group identified adolescent and young adult (AYA) patients with ALL, ranging in age between 15 and 39 years, as a unique subgroup with specific characteristics and needs [61,62]. Although >80–90% of children with ALL are cured of their disease, outcomes historically were much poorer for AYAs, with EFS ranging from 30% to 45% and survival appeared to plateau in the 1990s [63–67]. The most significant reason that could account for this disparity in outcomes is that ALL in AYAs has different biology from ALL in children, as leukemia cells in older patients typically have more genetic alterations.